Oxybutynin Hydrochloride Brillpharma 2.5mg/5ml Oral Solution

Urology

Therapeutic indications include:

  1. Urinary incontinence
  2. Urgency and frequency in the unstable bladder – whether due to neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as multiple sclerosis and spina bifida, or to idiopathic detrusor instability (motor urge incontinence)

Paediatric population

Indicated in children over 5 years of age for:

  1. Urinary incontinence, urgency and frequency in unstable bladder conditions due to idiopathic overactive bladder or neurogenic bladder disorders (detrusor overactivity).
  2. Nocturnal enuresis associated with detrusor overactivity, in conjunction with non-drug therapy, when other treatment has failed.1
Strength 2.5mg/ 5ml
Pack Size 150 ml
Measuring Device 5ml oral syringe with adaptor (graduated at every 0.5 ml)
Regulatory Status POM
Flavour Raspberry
Suitable for Vegetarians Yes
GTIN 5060712420003
PIP code 1238567

1 Summary of Product Characteristics (SPCs) and Patient Information Leaflets (PILs) can be found on the EMC website: https://www.medicines.org.uk/emc/product/13841/smpc

Manufacturing

Our quality and safety teams monitor and analyse each stage of the production and distribution process to make sure our products are of the highest quality. The application of Good Manufacturing Practice (GMP) means that we have the appropriate standards and procedures in place to help us achieve this.

How to report adverse events

Adverse events should be reported.

If you are based in the UK, reporting forms and information can be found at: https://yellowcard.mhra.gov.uk.

Adverse events should also be reported to Brill Pharma
Tel: 0044 (0) 1582 545505 Email: info@brillpharma.co.uk

If you are based outside of the UK, please report adverse events to Brill Pharma using the contact details provided above.

Have a question?

If you have a question about Brill Pharma or any products in our range please get in touch

Tel: 0044 (0) 1582 545505 Email: info@brillpharma.co.uk

Job Number: BLL-007-005Date of Preparation: March 2023